Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Setmelanotide in Patients With POMC/PCSK1, LEPR, NCOA1(SRC1), or SH2B1 Gene Variants in the Melanocortin-4 Receptor Pathway
NCT05093634Phase 3Completed
- Sponsor
- Rhythm Pharmaceuticals
- Start
- Dec 2021
- Primary completion
- Dec 2025
- Modality
- Peptides, Small Molecules
- Countries
- 10
01
Overview
A Phase 3 trial of setmelanotide in obesity, sponsored by Rhythm Pharmaceuticals. Started Dec 2021; status: completed.
02
Drugs
setmelanotide
03
Conditions
obesity
Beyond the preview
Go deeper on NCT05093634.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05093634.